SOPHiA GENETICS (SOPH) CMO sells 5,000 shares in Rule 10b5-1 trade
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported an open-market sale of 5,000 Ordinary Shares on June 25, 2026 at a weighted average price of $5.5049 per share. The transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Following this sale, Menu directly holds 240,780 Ordinary Shares, indicating he retained a substantial position in the company.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 5,000 shares ($27,525)
Net Sell
1 txn
Insider
Menu Philippe
Role
Chief Medical Officer
Sold
5,000 shs ($28K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 5,000 | $5.5049 | $28K |
Holdings After Transaction:
Ordinary Shares — 240,780 shares (Direct)
Footnotes (1)
- Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.30 to $5.69, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Shares sold: 5,000 shares
Weighted average sale price: $5.5049 per share
Post-transaction holdings: 240,780 shares
+1 more
4 metrics
Shares sold
5,000 shares
Ordinary Shares sold on June 25, 2026
Weighted average sale price
$5.5049 per share
Open-market sale on June 25, 2026
Post-transaction holdings
240,780 shares
Ordinary Shares held directly after sale
Sale price range
$5.30–$5.69 per share
Range of individual trades within the transaction
Key Terms
Rule 10b5-1(c), weighted average price, open-market sale, Ordinary Shares
4 terms
Rule 10b5-1(c) regulatory
"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
Was the SOPHiA GENETICS (SOPH) insider sale made under a Rule 10b5-1 plan?
Yes. The filing states the transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Such plans allow insiders to pre-schedule trades, helping separate routine portfolio management decisions from potential informational timing concerns.